Ali Valadkhani

Ali Valadkhani

Auto-generated profile, based on publicly available information

Ali Valadkhani

Clinical Research Development Unit, Kowsar Educational, Research and Therapeutic Hospital, Semnan University of Medical Sciences, Semnan, Iran

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2024 in Immunopathologia Persa
Verified
Journal Article
Open access
PDF file
MAMehrdad Abbaszadeh
Mehrdad Abbaszadeh
FBFahimeh Bayrami
Fahimeh Bayrami
SZSamaneh Zandifar
Samaneh Zandifar
HHHamid Reza Hemmati
Hamid Reza Hemmati
AVAli Valadkhani
Ali Valadkhani
APAlireza Peimanfar
Alireza Peimanfar
Introduction: Colorectal malignancy is the third furthermost frequent malignancy in the world, and approximately 80% of the cases are related to nongenetic causes, including high cholesterol levels. Accordingly, the present systematic review and meta-analysis aimed to investigate the relationship between statin treatment and the risk of colorectal cancer. Materials and Methods: The current study was a systematic review and meta-analysis designed based on PRISMA. International databases, including PubMed, Scopus, Web of Science, Cochrane, and Google Scholar search engine, were used to search for studies published until July 7, 2023. Data analysis was directed by STATA software version 14, and P values below than 0.05 (P<0.05) indicated the significance of statistical tests. Results: The results obtained from a combination of 30 studies with 2436650 samples indicated that statin use increased the risk of colorectal malignancy by 11% (OR: 0.89; 95% CI: 0.84, 0.95) and reduced the risk of rectal cancer by 16% (R: 0.84; 95% CI: 0.74, 0.94). Instead, statin administration reduced the hazard of colorectal cancer in individuals aged 50 to 59 by 22% (R: 0.78; 95% CI: 0.63, 0.95), 60 to 69 by 14% (OR: 0.86; 95% CI: 0.75, 0.98), and 70 to 79 by 8% (OR: 0.92; 95% CI: 0.87, 0.98). Utilization of statin in male (OR: 0.71; 95% CI: 0.58, 0.87) and female (OR: 0.84; 95% CI: 0.77, 0.92) patients reduced the risk of colorectal cancer by 29% and 16%, respectively. Furthermore, statin use in men (OR: 0.41; 95% CI: 0.26, 0.67) and women (OR: 0.64; 95% CI: 0.42, 0.97) reduced the risk of colon cancer by 59% and 36%, respectively. Conclusion: Statin administration reduced the risk of colorectal cancer, and the possibility of reduction in risk of colorectal cancer at lower ages was higher than in older adults and also higher in males compared with females. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (CRD42023450984) and Research Registry (UIN: reviewregistry1779) website.

23 April 2025 in Journal of Parathyroid Disease
Verified
Journal Article
Open access
PDF file
MFMajid Foroutan
Majid Foroutan
AVAli Valadkhani
Ali Valadkhani
MMMohammad Reza Moonesan
Mohammad Reza Moonesan
PTParisa Tajdini
Parisa Tajdini
Primary hyperparathyroidism (PHPT) is a common endocrine disorder characterized by the overproduction of parathyroid hormone (PTH), leading to disrupted calcium metabolism and hypercalcemia. Previously, PHPT was recognized as a symptomatic disease with severe skeletal, renal and neuromuscular manifestations. However, the advent of routine calcium screening has shifted the clinical profile toward milder, often asymptomatic presentations, particularly in developed countries. Despite this evolution, significant global disparities persist in the prevalence, clinical presentation and management of PHPT. In developing regions, symptomatic cases with advanced complications remain prevalent, driven by limited access to diagnostic resources, nutritional deficiencies and genetic factors. Exploring the evolving clinical profiles of this disease from a global perspective emphasizes regional variations in epidemiology, etiology and treatment approaches, examines the impact of socioeconomic, environmental, and genetic factors on the disease’s presentation and outcomes and addresses the challenges of diagnosis and management in resource-limited settings.

23 April 2025 in Journal of Parathyroid Disease
Verified
Journal Article
Open access
PDF file
MFMajid Foroutan
Majid Foroutan
AVAli Valadkhani
Ali Valadkhani
MMMohammad Reza Moonesan
Mohammad Reza Moonesan
PTParisa Tajdini
Parisa Tajdini
The parathyroid-leptin axis represents a network of hormonal interactions that play a critical role in regulating calcium homeostasis, energy balance, and metabolic health. The parathyroid hormone, primarily responsible for maintaining calcium and phosphate balance, interacts intricately with leptin, a hormone secreted by adipose tissue that regulates appetite, energy expenditure, and bone metabolism. This interplay involves both direct and indirect mechanisms, including leptin’s influence on parathormone (PTH) secretion and PTH’s modulation of leptin signaling in adipose tissue. Calcium and vitamin D further fine-tune this axis, creating a feedback loop that integrates bone, adipose, and metabolic functions. Dysregulation of the parathyroid-leptin axis has been implicated in various pathological conditions, such as osteoporosis, obesity, and metabolic disorders, highlighting its significance in maintaining physiological homeostasis. This review explores the mechanisms underlying the parathyroid-leptin axis, its physiological and pathological implications, and its potential as a therapeutic target for metabolic and bone-related diseases.